JPWO2020018975A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020018975A5 JPWO2020018975A5 JP2021502987A JP2021502987A JPWO2020018975A5 JP WO2020018975 A5 JPWO2020018975 A5 JP WO2020018975A5 JP 2021502987 A JP2021502987 A JP 2021502987A JP 2021502987 A JP2021502987 A JP 2021502987A JP WO2020018975 A5 JPWO2020018975 A5 JP WO2020018975A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alkyl
- cycloalkyl
- halogen
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 42
- 125000000753 cycloalkyl group Chemical group 0.000 claims 34
- 229910052736 halogen Inorganic materials 0.000 claims 32
- 150000002367 halogens Chemical class 0.000 claims 29
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000000623 heterocyclic group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 25
- 239000012453 solvate Substances 0.000 claims 25
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 22
- 125000001424 substituent group Chemical group 0.000 claims 18
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 229910052805 deuterium Inorganic materials 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 8
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- 230000007812 deficiency Effects 0.000 claims 6
- 208000017169 kidney disease Diseases 0.000 claims 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 6
- 208000026278 immune system disease Diseases 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 claims 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 208000009766 Blau syndrome Diseases 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 4
- 201000003274 CINCA syndrome Diseases 0.000 claims 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 4
- 208000035690 Familial cold urticaria Diseases 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 206010072219 Mevalonic aciduria Diseases 0.000 claims 4
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 206010000496 acne Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 4
- 208000002557 hidradenitis Diseases 0.000 claims 4
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010065159 Polychondritis Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000008494 pericarditis Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- 208000012414 A20 haploinsufficiency Diseases 0.000 claims 2
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 2
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000022210 Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010063094 Cerebral malaria Diseases 0.000 claims 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010061788 Corneal infection Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 241001475178 Dira Species 0.000 claims 2
- 208000021866 Dressler syndrome Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 108010034143 Inflammasomes Proteins 0.000 claims 2
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010031149 Osteitis Diseases 0.000 claims 2
- 206010031252 Osteomyelitis Diseases 0.000 claims 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
- 208000033182 PLCG2-associated antibody deficiency and immune dysregulation Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 241000876474 Sapho Species 0.000 claims 2
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 2
- 201000010001 Silicosis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000010265 Sweet syndrome Diseases 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 208000007474 aortic aneurysm Diseases 0.000 claims 2
- 206010003441 asbestosis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000018339 bone inflammation disease Diseases 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 2
- 231100000874 brain damage Toxicity 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims 2
- 208000004593 pneumococcal meningitis Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 2
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 206010012559 Developmental delay Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000009777 Majeed syndrome Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000025255 bacterial arthritis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 208000031162 sideroblastic anemia Diseases 0.000 claims 1
- 201000005956 sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701313P | 2018-07-20 | 2018-07-20 | |
| US62/701,313 | 2018-07-20 | ||
| PCT/US2019/042711 WO2020018975A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532101A JP2021532101A (ja) | 2021-11-25 |
| JPWO2020018975A5 true JPWO2020018975A5 (enExample) | 2022-07-25 |
| JP7320595B2 JP7320595B2 (ja) | 2023-08-03 |
Family
ID=67659954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502987A Active JP7320595B2 (ja) | 2018-07-20 | 2019-07-19 | インターロイキン－１活性の阻害剤としてのスルホンイミドアミド化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12234245B2 (enExample) |
| EP (1) | EP3823974A1 (enExample) |
| JP (1) | JP7320595B2 (enExample) |
| KR (1) | KR20210034596A (enExample) |
| CN (1) | CN112513048A (enExample) |
| AR (1) | AR115822A1 (enExample) |
| AU (1) | AU2019306658A1 (enExample) |
| BR (1) | BR112021001044A2 (enExample) |
| CA (1) | CA3105521A1 (enExample) |
| CL (1) | CL2021000153A1 (enExample) |
| CO (1) | CO2021001530A2 (enExample) |
| CR (1) | CR20210022A (enExample) |
| IL (1) | IL279256A (enExample) |
| MA (1) | MA53172A (enExample) |
| MX (1) | MX2021000780A (enExample) |
| PE (1) | PE20211811A1 (enExample) |
| PH (1) | PH12021500005A1 (enExample) |
| SG (1) | SG11202013062VA (enExample) |
| TW (1) | TWI825134B (enExample) |
| UA (1) | UA128558C2 (enExample) |
| WO (1) | WO2020018975A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7163293B2 (ja) | 2017-01-23 | 2022-10-31 | ジェネンテック， インコーポレイテッド | インターロイキン－１活性の阻害剤としての化学化合物 |
| CN117209447A (zh) | 2017-07-24 | 2023-12-12 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| WO2019068772A1 (en) | 2017-10-03 | 2019-04-11 | Inflazome Limited | NEW COMPOUNDS |
| PE20211811A1 (es) | 2018-07-20 | 2021-09-14 | Hoffmann La Roche | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 |
| CA3104199A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| CN120531732A (zh) * | 2018-11-13 | 2025-08-26 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| US12134611B2 (en) | 2018-11-13 | 2024-11-05 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| ES2974842T3 (es) | 2018-11-13 | 2024-07-01 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp |
| US20230051589A1 (en) * | 2018-11-16 | 2023-02-16 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2020154499A1 (en) * | 2019-01-23 | 2020-07-30 | Novartis Inflammasome Research, Inc. | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity |
| US20220378801A1 (en) | 2019-06-21 | 2022-12-01 | Ac Immune Sa | Novel compounds |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| CA3151865A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms) |
| JP7595642B2 (ja) | 2019-07-17 | 2024-12-06 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| JP7392169B2 (ja) * | 2019-11-12 | 2023-12-05 | 成都百裕制薬股▲ふん▼有限公司 | アミド誘導体及びその調製方法並びに医薬における応用 |
| WO2021150574A1 (en) * | 2020-01-22 | 2021-07-29 | Genentech, Inc. | Sulfonimidamide compounds as nlrp3 modulators |
| JP2023518044A (ja) * | 2020-03-16 | 2023-04-27 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| CA3174837A1 (en) | 2020-04-15 | 2021-10-21 | Daniel Oehlrich | Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway |
| MX2022012896A (es) | 2020-04-15 | 2022-11-09 | Janssen Pharmaceutica Nv | Pirrolo[1,2-d][1,2,4]triazin-2-ilacetamidas como inhibidores de la ruta del inflamasoma nlrp3. |
| US20230203064A1 (en) | 2020-04-23 | 2023-06-29 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of nlrp3 |
| KR20230005320A (ko) * | 2020-04-30 | 2023-01-09 | 얀센 파마슈티카 엔.브이. | 신규 트리아지노인돌 화합물 |
| AU2021279305A1 (en) | 2020-05-28 | 2023-02-09 | Janssen Pharmaceutica Nv | Compounds |
| CA3178361A1 (en) | 2020-06-19 | 2021-12-23 | Emanuele Gabellieri | Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway |
| EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
| CA3189887A1 (en) | 2020-09-24 | 2022-03-31 | Daniel Oehlrich | New compounds |
| CN114539256B (zh) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 三环化合物及其医药用途 |
| MX2023010223A (es) | 2021-03-04 | 2023-09-11 | Janssen Pharmaceutica Nv | Derivados de 4-amino-6-oxo-piridazina que modulan la nlrp3. |
| WO2022184842A1 (en) | 2021-03-04 | 2022-09-09 | Janssen Pharmaceutica Nv | 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3 |
| CA3212725A1 (en) | 2021-04-29 | 2022-11-03 | Daniel Oehlrich | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| WO2022237782A1 (zh) * | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| WO2022237781A1 (zh) * | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| WO2023275230A1 (en) | 2021-07-01 | 2023-01-05 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
| EP4373826A1 (en) * | 2021-07-19 | 2024-05-29 | Genentech, Inc. | Sulfonimidamde compounds and uses thereof |
| CN115894478B (zh) * | 2021-09-30 | 2025-04-04 | 杭州民生药物研究院有限公司 | 一种新型吡啶并吡唑类杂环化合物及其应用 |
| US20250109126A1 (en) | 2021-12-22 | 2025-04-03 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| CN116804018A (zh) * | 2022-03-25 | 2023-09-26 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| CN117247393A (zh) * | 2022-06-17 | 2023-12-19 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| WO2024010772A1 (en) * | 2022-07-06 | 2024-01-11 | Kodiak Sciences Inc. | Nlrp3 inhibitors |
| JP2025524640A (ja) | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| CN119998284A (zh) | 2022-07-28 | 2025-05-13 | Ac免疫有限公司 | 新化合物 |
| IL319619A (en) | 2022-09-23 | 2025-05-01 | Merck Sharp & Dohme Llc | Phthalazine derivatives used as NOD-LIKE PROTEIN 3 receptor inhibitors |
| WO2024249539A1 (en) | 2023-06-02 | 2024-12-05 | Merck Sharp & Dohme Llc | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
| WO2025101716A1 (en) * | 2023-11-07 | 2025-05-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Processes for synthesis of trifunctionalized sulfur(vi) compounds |
| TW202535370A (zh) | 2023-12-14 | 2025-09-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之吲唑衍生物 |
| US20250223290A1 (en) | 2023-12-14 | 2025-07-10 | Merck Sharp & Dohme Llc | Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| US20250326772A1 (en) | 2024-04-19 | 2025-10-23 | Kyorin Pharmaceutical Co., Ltd. | Mrgprx2 antagonists, pharmaceutical composition including mrgprx2 antagonist, and method of treating mrgprx2-mediated disease or disorder |
| CN119100956B (zh) * | 2024-09-03 | 2025-12-02 | 大连理工大学 | 一种无催化剂的光驱动合成亚磺酰胺类化合物的方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4705555A (en) * | 1984-08-08 | 1987-11-10 | E. I. Du Pont De Nemours And Company | Herbicidal triazines |
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| DE19540995A1 (de) | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| BR9714328A (pt) | 1997-01-29 | 2000-03-21 | Pfizer | da atividade de interleucina-1 |
| CA2383026A1 (en) | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| WO2003045400A1 (en) | 2001-11-30 | 2003-06-05 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| MX341482B (es) | 2010-02-22 | 2016-08-22 | Raqualia Pharma Inc | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. |
| US20140221340A1 (en) | 2011-09-02 | 2014-08-07 | Kyowa Hakko Kirin Co., Ltd. | Chemokine receptor activity regulator |
| WO2014190015A1 (en) | 2013-05-21 | 2014-11-27 | Virginia Commonwealth University | Cryopyrin inhibitors for preventing and treating inflammation |
| MY193765A (en) * | 2015-02-16 | 2022-10-27 | Univ Queensland | Sulfonylureas and related compounds and use of same |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| US11858922B2 (en) | 2016-02-16 | 2024-01-02 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| JP7050751B2 (ja) | 2016-04-18 | 2022-04-08 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
| JP7163293B2 (ja) | 2017-01-23 | 2022-10-31 | ジェネンテック， インコーポレイテッド | インターロイキン－１活性の阻害剤としての化学化合物 |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| US11236045B2 (en) | 2017-06-09 | 2022-02-01 | Cadila Healthcare Limited | Substituted sulfoximine compounds |
| HRP20220195T1 (hr) | 2017-07-07 | 2022-04-15 | Inflazome Limited | Novi spojevi sulfonamid karboksamida |
| WO2019008029A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| CN117209447A (zh) * | 2017-07-24 | 2023-12-12 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| CN111132974B (zh) | 2017-08-15 | 2023-11-21 | 英夫拉索姆有限公司 | 新颖的磺酰胺羧酰胺化合物 |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3668601A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| PE20200758A1 (es) | 2017-08-15 | 2020-07-27 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 |
| EP3668862A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| WO2019068772A1 (en) * | 2017-10-03 | 2019-04-11 | Inflazome Limited | NEW COMPOUNDS |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CA3078195A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| CA3103664A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
| JP2021529187A (ja) | 2018-07-03 | 2021-10-28 | ノバルティス アーゲー | Ｎｌｒｐモジュレータ |
| PE20211811A1 (es) | 2018-07-20 | 2021-09-14 | Hoffmann La Roche | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 |
| US10981918B2 (en) | 2018-07-20 | 2021-04-20 | Grünenthal GmbH | Further substituted triazolo quinoxaline derivatives |
| CA3104199A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| PE20211333A1 (es) | 2018-08-15 | 2021-07-22 | Inflazome Ltd | Compuestos de sulfonamidaurea novedosos |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2022505525A (ja) | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| US12134611B2 (en) | 2018-11-13 | 2024-11-05 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| CN120531732A (zh) | 2018-11-13 | 2025-08-26 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| US20230051589A1 (en) | 2018-11-16 | 2023-02-16 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| WO2020154321A1 (en) | 2019-01-22 | 2020-07-30 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2020154499A1 (en) | 2019-01-23 | 2020-07-30 | Novartis Inflammasome Research, Inc. | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity |
| CN118221763A (zh) | 2019-03-29 | 2024-06-21 | 免疫医疗有限公司 | 化合物及其缀合物 |
| US20220378801A1 (en) | 2019-06-21 | 2022-12-01 | Ac Immune Sa | Novel compounds |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| EP4077326A4 (en) | 2019-12-19 | 2024-04-24 | Jacobio Pharmaceuticals Co., Ltd. | KRAS MUTANT PROTEIN INHIBITORS |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| TWI785474B (zh) | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| WO2021150574A1 (en) | 2020-01-22 | 2021-07-29 | Genentech, Inc. | Sulfonimidamide compounds as nlrp3 modulators |
| JP7736313B2 (ja) | 2020-01-29 | 2025-09-09 | ウニバシタット デ レス イレス バレアース | αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用 |
| US20230203064A1 (en) | 2020-04-23 | 2023-06-29 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of nlrp3 |
| KR20230005320A (ko) | 2020-04-30 | 2023-01-09 | 얀센 파마슈티카 엔.브이. | 신규 트리아지노인돌 화합물 |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| AU2021279305A1 (en) | 2020-05-28 | 2023-02-09 | Janssen Pharmaceutica Nv | Compounds |
| CA3178361A1 (en) | 2020-06-19 | 2021-12-23 | Emanuele Gabellieri | Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway |
| IL277528B (en) | 2020-09-22 | 2022-05-01 | Ag Plenus Ltd | Herbicidal compounds and methods of their use |
| CA3189887A1 (en) | 2020-09-24 | 2022-03-31 | Daniel Oehlrich | New compounds |
| WO2022184842A1 (en) | 2021-03-04 | 2022-09-09 | Janssen Pharmaceutica Nv | 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3 |
| CA3212725A1 (en) | 2021-04-29 | 2022-11-03 | Daniel Oehlrich | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| WO2022237781A1 (zh) | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| WO2023275230A1 (en) | 2021-07-01 | 2023-01-05 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
-
2019
- 2019-07-19 PE PE2021000082A patent/PE20211811A1/es unknown
- 2019-07-19 CN CN201980048375.6A patent/CN112513048A/zh active Pending
- 2019-07-19 UA UAA202100695A patent/UA128558C2/uk unknown
- 2019-07-19 WO PCT/US2019/042711 patent/WO2020018975A1/en not_active Ceased
- 2019-07-19 EP EP19753515.6A patent/EP3823974A1/en active Pending
- 2019-07-19 MA MA053172A patent/MA53172A/fr unknown
- 2019-07-19 SG SG11202013062VA patent/SG11202013062VA/en unknown
- 2019-07-19 CA CA3105521A patent/CA3105521A1/en active Pending
- 2019-07-19 JP JP2021502987A patent/JP7320595B2/ja active Active
- 2019-07-19 BR BR112021001044-0A patent/BR112021001044A2/pt unknown
- 2019-07-19 AU AU2019306658A patent/AU2019306658A1/en not_active Abandoned
- 2019-07-19 MX MX2021000780A patent/MX2021000780A/es unknown
- 2019-07-19 CR CR20210022A patent/CR20210022A/es unknown
- 2019-07-19 KR KR1020217002210A patent/KR20210034596A/ko not_active Withdrawn
- 2019-07-22 AR ARP190102055A patent/AR115822A1/es not_active Application Discontinuation
- 2019-07-22 TW TW108125886A patent/TWI825134B/zh not_active IP Right Cessation
-
2020
- 2020-12-07 IL IL279256A patent/IL279256A/en unknown
-
2021
- 2021-01-15 US US17/150,349 patent/US12234245B2/en active Active
- 2021-01-19 CL CL2021000153A patent/CL2021000153A1/es unknown
- 2021-01-19 PH PH12021500005A patent/PH12021500005A1/en unknown
- 2021-02-10 CO CONC2021/0001530A patent/CO2021001530A2/es unknown
-
2024
- 2024-12-19 US US18/988,433 patent/US20250115618A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020018975A5 (enExample) | ||
| JPWO2020018970A5 (enExample) | ||
| JP2020505381A5 (enExample) | ||
| JP2018510207A5 (enExample) | ||
| JP2024178191A5 (enExample) | ||
| RU2711502C2 (ru) | Гетероциклические производные и их применение | |
| JP2020502047A5 (enExample) | ||
| HRP20220195T1 (hr) | Novi spojevi sulfonamid karboksamida | |
| JP2021105002A5 (enExample) | ||
| JP2018520161A5 (enExample) | ||
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| JP2016526576A5 (enExample) | ||
| JP6945605B2 (ja) | ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用 | |
| JP2013533884A5 (enExample) | ||
| JP2016532669A5 (enExample) | ||
| RU2016115487A (ru) | Тиазолопиримидиноны в качестве модуляторов активности рецепторов nmda | |
| IL294536A (en) | Sulfonimidamide compounds as nlrp3 modulators | |
| JP2021500340A5 (enExample) | ||
| JP2016028076A5 (enExample) | ||
| JPWO2023072197A5 (enExample) | ||
| JP2020503332A5 (enExample) | ||
| JP2025113368A (ja) | 多形カルバゾール誘導体およびその使用 | |
| JP2008504362A (ja) | Ｐ２ｘ７阻害活性をもつ５−［４−（２−ヒドロキシ−エチル）−３，５−ジオキソ−４，５−ジヒドロ−３ｈ−［１，２，４］トリアジン−２−イル］−ベンズアミド誘導体を、トリアジンの４−位において置換されていない誘導体とオキシランをルイス酸の存在下で反応させることにより製造する方法 | |
| AU2020338985A1 (en) | Substituted urea dihydroorotate dehydrogenase inhibitors | |
| HRP20240896T1 (hr) | Derivati sulfoniluree i njihova upotreba |